Phase II trial of imatinib mesylate (I) in combination with docetaxel (D) in the treatment of patients (pts) with recurrent or persistent epithelial ovarian carcinoma (EOC)
| العنوان: | Phase II trial of imatinib mesylate (I) in combination with docetaxel (D) in the treatment of patients (pts) with recurrent or persistent epithelial ovarian carcinoma (EOC) |
|---|---|
| المؤلفون: | T. O'Brien, N. Kazmi, L. A. Winkelman, M. L. Larson, J. Rotmensch, L. Usha |
| المصدر: | Journal of Clinical Oncology. 27:e16552-e16552 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | Cancer Research, Imatinib mesylate, Oncology, Docetaxel, Epithelial ovarian carcinoma, medicine.drug_class, business.industry, Immunology, Cancer research, medicine, business, Tyrosine-kinase inhibitor, medicine.drug |
| الوصف: | e16552 Background: D has a known single-agent activity in advanced EOC with the response rate of at least 10%. I is a multi-targeted tyrosine kinase inhibitor shown in preclinical studies to decrease interstitial pressure in the tumor and facilitate influx of chemotherapeutic agents into the tumor. Methods: A single-institution trial was conducted in pts with advanced EOC in 2005–2007. The primary endpoint of the study was to determine a tumor response to the study combination. Pts were required to have received 1 or 2 prior chemotherapeutic regimens including a platinum compound and have performance status 0–2. Pts were to receive D 60 mg/m2 IV every 3 weeks and I 400 mg/day by mouth continuously. Planned target accrual for the first stage of the study was 15 pts with the preset minimum of 3 responses to proceed to the second stage. Tumor response was evaluated by RECIST criteria after every 3 cycles of D. Treatment was continued until disease progression or unacceptable toxicity. Results: Study was terminated early due to lack of response and significant toxicities. A total of 10 pts were enrolled. The age range of the pts was 55–79 with the mean age = 64. Five pts were evaluable for response and in all of them, cancer progression was observed after 3 cycles of combination therapy (0 responses). Five pts were taken off the study after 1 cycle of treatment either due to serious adverse events (SAEs) or disease progression. Among grade 3 and 4 SAE's observed in the study were 4 cases of hematological toxicity, 1 case of rash, 1 case of dizziness, and 1 case of deep venous thrombosis. The median progression-free survival for pts on the study was 7.5 weeks. Conclusions: Although the sample size of this study was small, the combination of I and D at the above doses appears ineffective in the population of moderately-pretreated women with advanced EOC. The majority of grade 3 and 4 SAE's were due to myelosuppression likely caused by D rather than I. No significant financial relationships to disclose. |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::2760cfac78a14470ce4a31d535fe816a https://doi.org/10.1200/jco.2009.27.15_suppl.e16552 |
| رقم الأكسشن: | edsair.doi...........2760cfac78a14470ce4a31d535fe816a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|